| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Ascendis Pharma A/s (ASND) have been net sellers, shedding 1,236 shares worth roughly $380K on balance.
ASND sits in the Biotechnology industry within the Healthcare sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 4.4K | $956.4K | - | |
| Dir | 4.0K | $1.06M | - | |
| Dir | 2.9K | $716.0K | - | |
| VP | 0 | - | - | |
| Other | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads | SVP &Pao | Sale+OE | 3,000 | $270.19 | $810,570.00 | - | - | - | |
| Sep 2, 2026 | Holtug Lars | Director | Sell | 236 | $264.13 | $62,334.59 | -5.6% | - | - | |
| Aug 14, 2026 | Bienaime Jean Jacques68 | Director | Buy | 2,000 | $246.33 | $492,654.00 | +222.2% | - | - | |
| Jun 2, 2026 | Smith Scott Thomas | EVP &Chief Financial Officer | Buy | 100 | $219.00 | $21,900.00 | +2.3% | +21.4% | - | |
| May 29, 2026 | Bienaime Jean Jacques68 | Director | Buy | 500 | $223.12 | $111,562.00 | +125.0% | +11.3% | - | |
| May 29, 2026 | Smith Scott Thomas | EVP &Chief Financial Officer | Buy | 250 | $223.32 | $55,830.00 | +6.2% | +11.3% | - | |
| May 26, 2026 | Bienaime Jean Jacques68 | Director | Buy | 400 | $237.80 | $95,120.50 | New | +5.1% | - | |
| May 11, 2026 | Jensen Flemming Steen | See Remarks | Sell | 19,460 | $238.49 | $4,641,021.24 | -100% | +7.1% | - |